Crossmark

Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers

Crossref DOI link: https://doi.org/10.1007/s10637-021-01099-1

Published Online: 2021-03-13

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hou, Ming-Mo

Ho, Ching-Liang

Lin, Hsuan-Yu

Zhu, Yunting

Zhang, Xiaodi
Funding

Funding for this research was provided by:

Shanghai Henlius Biotech, Inc.
License Information

Text and Data Mining valid from 2021-03-13

Version of Record valid from 2021-03-13
More Information

Article History

Received: 21 January 2021

Accepted: 9 March 2021

First Online: 13 March 2021

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: All participants provided written informed consent before admission and initiation of the study.

: Not applicable.

: Yunting Zhu and Xiaodi Zhang are employees of Henlius. All other authors declare no conflicts of interest.

Document is current

Any future updates will be listed below